← Aehr Test Systems overview
Aehr Test SystemsAEHR

Why is Aehr Test Systems (AEHR) moving?

Q3 2026
▲3▼1

Aehr's AI-driven turnaround: record bookings, but valuation and insider selling raise flags

  • Record bookings and backlog Aehr reported record bookings of $60.7 million and a backlog of $100.6 million, supporting fiscal 2027 revenue guidance of $130–150 million, nearly triple last year's level.

    This is the core new positive development that drove the quarter.

  • AI and silicon photonics demand AI processors and silicon photonics now account for 91–95% of revenue, replacing EV silicon carbide dependence, with repeat orders including $6 million from a hyperscale customer.

    Shows the successful shift to a hot new market, a key driver of the turnaround.

  • Earnings beat and profitability outlook Earnings beat estimates, and management expects a return to profitability, signaling improving financial health.

    Confirms the turnaround is translating into better financial results.

  • Valuation and insider selling risks The stock trades at roughly 81 times trailing sales, analysts see over 40% downside, and the CEO sold $5.2 million in shares—about 20% of his trust holdings—while the company still reports net losses.

    Highlights the major counterweight that could pressure the stock despite operational success.

August 2026
▲3▼1

Aehr's AI test orders and record backlog drive growth, but valuation and insider selling raise caution

  • Record backlog and strong fiscal 2027 guidance Aehr guided fiscal 2027 revenue to $130–$150 million, up to 200% growth, after record bookings of $60.7 million pushed backlog to $100.6 million. That backlog already covers 77% of the low end, giving investors confidence in future sales and pushing the stock up.

    This is the core new financial outlook that directly drives investor expectations for future revenue and profit.

  • Diversification into AI and silicon photonics pays off Aehr now gets 95% of revenue outside EV silicon carbide, with AI processors and silicon photonics making up 91% of last quarter's sales. New orders, including a $22 million AI processor order and silicon photonics production orders, show concrete demand and reduce reliance on the EV market.

    It shows the company successfully shifted its business to faster-growing AI markets, which supports higher future revenue.

  • New $6M follow-on order from hyperscale AI customer Aehr won about $6 million in follow-on orders from its lead hyperscale customer for testing next-generation AI processors. The equipment will ship over six months to a Taiwan partner, adding near-term revenue and confirming that demand from big AI chip makers is real and repeating.

    This is a fresh order that directly adds to revenue and validates the company's growth story with a major customer.

  • CEO sells $5.2 million in shares, valuation stretched CEO Gayn Erickson sold $5.2 million of stock, cutting his trust holdings by 20%, while the company still reports a net loss. The stock trades at a very high price-to-sales ratio, and insider selling can signal that even management sees the shares as fully valued, which may weigh on the price.

    It provides a real counterweight: insider selling and high valuation could limit further gains or trigger a pullback.

Latest
▲3▼1

Aehr's AI test orders and record backlog drive growth, but valuation and insider selling raise caution

  • Record backlog and strong fiscal 2027 guidance Aehr guided fiscal 2027 revenue to $130–$150 million, up to 200% growth, after record bookings of $60.7 million pushed backlog to $100.6 million. That backlog already covers 77% of the low end, giving investors confidence in future sales and pushing the stock up.

    This is the core new financial outlook that directly drives investor expectations for future revenue and profit.

  • Diversification into AI and silicon photonics pays off Aehr now gets 95% of revenue outside EV silicon carbide, with AI processors and silicon photonics making up 91% of last quarter's sales. New orders, including a $22 million AI processor order and silicon photonics production orders, show concrete demand and reduce reliance on the EV market.

    It shows the company successfully shifted its business to faster-growing AI markets, which supports higher future revenue.

  • New $6M follow-on order from hyperscale AI customer Aehr won about $6 million in follow-on orders from its lead hyperscale customer for testing next-generation AI processors. The equipment will ship over six months to a Taiwan partner, adding near-term revenue and confirming that demand from big AI chip makers is real and repeating.

    This is a fresh order that directly adds to revenue and validates the company's growth story with a major customer.

  • CEO sells $5.2 million in shares, valuation stretched CEO Gayn Erickson sold $5.2 million of stock, cutting his trust holdings by 20%, while the company still reports a net loss. The stock trades at a very high price-to-sales ratio, and insider selling can signal that even management sees the shares as fully valued, which may weigh on the price.

    It provides a real counterweight: insider selling and high valuation could limit further gains or trigger a pullback.

July 2026
▲3

Aehr's AI pivot drives record bookings and a bold 2027 revenue forecast

  • Record bookings and AI-driven revenue forecast Aehr reported record quarterly bookings of $60.7 million and guided fiscal 2027 revenue to $130–150 million, nearly triple last year's $50 million. Management says AI processors and silicon photonics are now the main growth drivers, with 71% of revenue from AI-related chips. This directly boosts investor expectations for future sales and profits.

    This is the core new event that explains the stock's surge and future growth outlook.

  • Earnings beat and return to profitability expected Aehr beat earnings estimates with non-GAAP EPS of $0.11 and revenue up 33% year-over-year to $18.8 million. Management expects non-GAAP net income to be 18–22% of revenue in fiscal 2027, signaling a return to profitability. This reassures investors that the company can convert strong demand into actual profits.

    It shows the financial health behind the stock move and supports the bullish case.

  • Successful pivot from EV chips to AI processors Aehr has shifted from relying on electric-vehicle silicon carbide chips to AI accelerators, CPUs, and network processors. Two years ago, over 95% of business was EV-related; now AI chips make up 71% of revenue. This diversification reduces dependence on a single market and taps into the massive AI infrastructure buildout.

    It explains the strategic transformation that is driving new orders and investor enthusiasm.

  • Valuation concerns and analyst caution Despite the strong news, Wall Street sees AEHR as overvalued. The consensus rating is Moderate Buy with a mean price target near $64, implying potential downside of over 40% from recent levels. The stock trades at 81 times trailing sales, so any disappointment could lead to a sharp pullback.

    It provides a fair counterweight to the bullish drivers and highlights the risk for new investors.

▲3

Aehr's AI pivot drives record bookings and a bold 2027 revenue forecast

  • Record bookings and AI-driven revenue forecast Aehr reported record quarterly bookings of $60.7 million and guided fiscal 2027 revenue to $130–150 million, nearly triple last year's $50 million. Management says AI processors and silicon photonics are now the main growth drivers, with 71% of revenue from AI-related chips. This directly boosts investor expectations for future sales and profits.

    This is the core new event that explains the stock's surge and future growth outlook.

  • Earnings beat and return to profitability expected Aehr beat earnings estimates with non-GAAP EPS of $0.11 and revenue up 33% year-over-year to $18.8 million. Management expects non-GAAP net income to be 18–22% of revenue in fiscal 2027, signaling a return to profitability. This reassures investors that the company can convert strong demand into actual profits.

    It shows the financial health behind the stock move and supports the bullish case.

  • Successful pivot from EV chips to AI processors Aehr has shifted from relying on electric-vehicle silicon carbide chips to AI accelerators, CPUs, and network processors. Two years ago, over 95% of business was EV-related; now AI chips make up 71% of revenue. This diversification reduces dependence on a single market and taps into the massive AI infrastructure buildout.

    It explains the strategic transformation that is driving new orders and investor enthusiasm.

  • Valuation concerns and analyst caution Despite the strong news, Wall Street sees AEHR as overvalued. The consensus rating is Moderate Buy with a mean price target near $64, implying potential downside of over 40% from recent levels. The stock trades at 81 times trailing sales, so any disappointment could lead to a sharp pullback.

    It provides a fair counterweight to the bullish drivers and highlights the risk for new investors.